TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05584670: A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Sponsor: Sanofi · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 542 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT05584670 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05584670 Rescue Dossier →